Clinical characteristics
Characteristics . | Positive, n (%) . |
|---|---|
| Sex; n = 83 | |
| Male | 35 (42.2) |
| Female | 48 (57.8) |
| Type of biopsy; n = 83 | |
| Stereotaxic | 50 (60.2) |
| Surgical | 33 (39.7) |
| Number of lesions; n = 83 | |
| 1 | 42 (50.6) |
| At least 2 | 41 (49.4) |
| Involvement of deep structures; n = 82 | |
| Absence | 37 (45.1) |
| Presence | 45 (54.9) |
| ECOG performance status; n = 82 | |
| 0 to 1 | 30 (36.6) |
| At least 2 | 52 (63.4) |
| CSF determination; n = 65 | |
| No tumor cells | 63 (96.9) |
| Presence of tumor cells | 2 (3.1) |
| LDH concentration; n = 53 | |
| Normal | 39 (73.6) |
| Elevated | 14 (26.4) |
| Histologic subtype*; n = 83 | |
| Centroblastic | 65 (78.3) |
| Immunoblastic | 7 (8.4) |
| Unclassifiable | 11 (13.3) |
Characteristics . | Positive, n (%) . |
|---|---|
| Sex; n = 83 | |
| Male | 35 (42.2) |
| Female | 48 (57.8) |
| Type of biopsy; n = 83 | |
| Stereotaxic | 50 (60.2) |
| Surgical | 33 (39.7) |
| Number of lesions; n = 83 | |
| 1 | 42 (50.6) |
| At least 2 | 41 (49.4) |
| Involvement of deep structures; n = 82 | |
| Absence | 37 (45.1) |
| Presence | 45 (54.9) |
| ECOG performance status; n = 82 | |
| 0 to 1 | 30 (36.6) |
| At least 2 | 52 (63.4) |
| CSF determination; n = 65 | |
| No tumor cells | 63 (96.9) |
| Presence of tumor cells | 2 (3.1) |
| LDH concentration; n = 53 | |
| Normal | 39 (73.6) |
| Elevated | 14 (26.4) |
| Histologic subtype*; n = 83 | |
| Centroblastic | 65 (78.3) |
| Immunoblastic | 7 (8.4) |
| Unclassifiable | 11 (13.3) |
Mean age for the 83 assessable patients in the study was 60 (range, 23-80). n indicates number of assessable patients; CSF, cerebrospinal fluid; LDH, lactate dehydrogenase.
According to the WHO classification